Novo Nordisk Sparks Debate: Bearish Mood Grows Despite $70 Price Target
HSBC’s bullish call collides with growing investor frustration amid execution risks and heavy restructuring moves
In the wake of a HSBC upgrade that lifted Novo Nordisk (ticker: NVO) from “Hold” to “Buy” with a newly minted $70 price target, sentiment in market forums is turning increasingly bearish. Traders and long-term holders express frustration over what they view as underperformance versus competitors like Eli Lilly (ticker: LLY), even as Novo remains a heavyweight in the healthcare and pharmaceutical sector.
Shares of NVO, which trade on the New York Stock Exchange (NYSE) as an ADR, have experienced notable volatility in recent sessions. The HSBC call briefly sparked a +6 % rally, but many investors caution that this was more a reaction to the upgrade than a reflection of underlying fundamentals. In contrast, Morgan Stanley issued a downgrade and slashed its target to $47, citing slowing growth and competitive headwinds that could dampen momentum.
On the corporate side, the mood isn’t any brighter for the bulls. Novo Nordisk announced the shutdown of its cell therapy unit, laying off nearly 250 employees as part of a broader cost-cutting program. The company also began layoffs in the United States, impacting several divisions, including legal and clinical development. Globally, the plan is to eliminate around 9,000 positions—roughly 11 % of its workforce—in an effort to simplify operations and rein in expenses.
Despite the cuts, Novo isn’t standing still. The company recently signed a licensing agreement with Omeros Corporation for Zaltenibart (OMS906), a MASP-3 inhibitor aimed at treating rare blood and kidney diseases, with potential payments of up to $2.1 billion, including $340 million upfront. This strategic deal complements its $4.7 billion acquisition of Akero Therapeutics, aimed at strengthening its MASH (metabolic dysfunction-associated steatohepatitis) portfolio.
These moves highlight a clear strategic shift: Novo is deliberately diversifying beyond GLP-1 and obesity treatments to build new growth pillars. Some analysts see this as a necessary rebalancing; others interpret it as a sign that its core franchise may be facing pressure. Indeed, competition from LLY’s Zepbound (tirzepatide) is growing, and much of Novo’s future hinges on the outcomes of late-stage clinical trials.
Investor sentiment is split. Skeptics point to execution risk: can Novo successfully absorb and integrate these new assets while simultaneously cutting costs? There’s also concern that the restructuring could distract management from its core operations. On the other hand, optimists remain bullish on the company’s pipeline, pointing to potential catalysts such as the REDEFINE4 study and ongoing Alzheimer’s semaglutide trials, which could provide meaningful upside momentum if successful.
In the end, NVO’s path forward is far less certain than the $70 price target implies. Yet, the magnitude of its moves—from mass layoffs and portfolio overhauls to strategic biotech deals—has positioned Novo Nordisk as one of the most closely watched stocks in the biotech and pharmaceutical space this quarter.